Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May;44(6):1036-1042.
doi: 10.1038/s41386-018-0278-3. Epub 2018 Nov 22.

Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia

Affiliations
Free PMC article

Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia

Hiroyoshi Takeuchi et al. Neuropsychopharmacology. 2019 May.
Free PMC article

Abstract

Although some studies have suggested that relapse may be associated with antipsychotic treatment resistance in schizophrenia, the number and quality of studies is limited. The current analysis included patients with a diagnosis of first-episode schizophrenia or schizoaffective disorder who met the following criteria: (1) referral to the First-Episode Psychosis Program between 2003 and 2013; (2) treatment with an oral second-generation antipsychotic according to a standardized treatment algorithm; (3) positive symptom remission; (4) subsequent relapse (i.e., second episode) in association with non-adherence; and (5) reintroduction of antipsychotic treatment with the same agent used to achieve response in the first episode. The following outcomes were used as an index of antipsychotic treatment response: changes in the brief psychiatric rating scale (BPRS) total and positive symptom scores and number of patients who achieved positive symptom remission and 20 and 50% response. A total of 130 patients were included in the analyses. Although all patients took the same antipsychotic in both episodes, there were significant episode-by-time interactions for all outcomes of antipsychotic treatment response over 1 year in favor of the first episode compared to the second episode (50% response rate: 48.7 vs. 10.4% at week 7; 88.2 vs. 27.8% at week 27, respectively). Although antipsychotic doses in the second episode were significantly higher than those in the first episode, results remained unchanged after adjusting for antipsychotic dose. The present findings suggest that antipsychotic treatment response is reduced or delayed in the face of relapse following effective treatment of the first episode of schizophrenia.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
a Changes in BPRS total scores over time in first vs. second episodes (N = 130). The mixed-model analysis revealed a significant interaction between episode and time (F = 13.8, df = 15, 2242, P < 0.001). ***P < 0.001, **P < 0.01, *P < 0.05. BPRS brief psychiatric rating scale. b Changes in BPRS positive symptom scores over time in first vs. second episodes (N = 130). The mixed-model analysis revealed a significant interaction between episode and time (F = 20.5, df = 15, 2288, P < 0.0001). ***P < 0.001, **P < 0.01, *P < 0.05. BPRS brief psychiatric rating scale
Fig. 2
Fig. 2
Changes in positive symptom remission rates over time in first vs. second episodes (N = 130). The generalized estimating equation analysis revealed a significant interaction between episode and time (F = 95.0, P < 0.001). ***P < 0.001, **P < 0.01
Fig. 3
Fig. 3
a Changes in 20% response rates over time in first vs. second episodes (N = 130). The generalized estimating equation analysis revealed a significant interaction between episode and time (F = 75.2, P < 0.001). ***P < 0.001, **P < 0.01. b Changes in 50% response rates over time in first vs. second episodes (N = 130). The generalized estimating equation analysis revealed a significant interaction between episode and time (F = 105.0, P < 0.001). ***P < 0.001, **P < 0.01

Similar articles

Cited by

References

    1. Pennington M, McCrone P. The cost of relapse in schizophrenia. Pharmacoeconomics. 2017;35:921–36. doi: 10.1007/s40273-017-0515-3. - DOI - PubMed
    1. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379:2063–71. doi: 10.1016/S0140-6736(12)60239-6. - DOI - PubMed
    1. Sendt KV, Tracy DK, Bhattacharyya S. A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Res. 2015;225:14–30. doi: 10.1016/j.psychres.2014.11.002. - DOI - PubMed
    1. Mojtabai R, Lavelle J, Gibson PJ, Sohler NL, Craig TJ, Carlson GA, et al. Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996. Psychiatr Serv. 2002;53:337–9. doi: 10.1176/appi.ps.53.3.337. - DOI - PubMed
    1. Higashi K, Medic G, Littlewood KJ, Diez T, Granström O, Hert M, De Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3:200–18. doi: 10.1177/2045125312474019. - DOI - PMC - PubMed

Publication types

Substances